Ayantika Banerjee

Ayantika Banerjee

Auto-generated profile, based on publicly available information

Ayantika Banerjee

The Framingham Heart Study

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
VLVasileios-Arsenios Lioutas
Vasileios-Arsenios Lioutas
GPGina Peloso
Gina Peloso
JRJose Romero
Jose Romero
HAHugo Aparicio
Hugo Aparicio
MGMitzi Gonzales
Mitzi Gonzales
SSSudha Seshadri
Sudha Seshadri
Background: The association between transient ischemic attack (TIA) and dementia is incompletely characterized. Determining the cognitive sequalae of TIA is important as it can function as an early warning sign or additional risk factor for dementia. We sought to determine the long‐term incidence of post‐TIA dementia and examined whether TIA prompts changes in vascular risk factors. Methods: Nested matched longitudinal cohort study within the community‐based Framingham Heart Study. A prospectively collected sample of participants without dementia or transient ischemic attack were matched on age and sex (5:1) to participants with first incident TIA >60 years. The primary outcome of interest was the 20‐year incidence of all‐cause dementia. Results: The study matched 297 participants with TIA, 141 (47%) men, mean age 72.7±7.7 years, with 1485 controls without TIA. People with TIA were more likely to have hypertension, coronary heart disease, and atrial fibrillation. Over a median of 8.9 years of follow up, 57 (19%) participants with TIA and 353 (24%) controls without TIA developed dementia (hazard ratio [HR], 0.93 [95% CI, 0.71–1.24], P =0.63). Adjusting for stroke and accounting for the competing risk of death did not alter this association. Participants with TIA were more likely to have a reduction in the frequency of smoking (18% to 11%, P =0.025), an increase in anticoagulant use from 3% to 18%, ( P =0.0005), and a marginal increase in aspirin use (46% to 61%, P =0.052). Conclusions: We found no significant difference in dementia incidence over a 20‐year follow‐up period compared with matched TIA‐free controls. Our findings suggest that TIA prompts treatment changes and behavioral shifts that lower cardiovascular risk. Whether these are sufficient to mitigate subsequent dementia risk remains to be tested in prospective randomized studies.

3 September 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
MMMartin Mulligan
Martin Mulligan
ABAlexa S Beiser
Alexa S Beiser
AOAdrienne O’DOnnell
Adrienne O’DOnnell
ABAyantika Banerjee
Ayantika Banerjee
SGSaptaparni Ghosh
Saptaparni Ghosh
EMEmer R McGrath
Emer R McGrath
Background: The relationship between blood pressure (BP) trajectories across early (∼40 years) into mid-life (∼55 years) and preclinical dementia has not previously been well studied using positron emission tomography (PET) imaging outcomes. Objective: To examine the association between BP trajectories across early mid-life into mid mid-life and amyloid- and tau-PET burden in adults without clinical dementia. Methods: This prospective cohort study included dementia-free Framingham Heart Study 3 rd generation participants with data on remote BP (2002–2005) and recent BP (2016–2019) who participated in 11 C-Pittsburgh Compound-B (PiB)-PET and/or 18 F-Flortaucipir (FTP)-PET scans between 2016 to 2022. Outcomes included global amyloid deposition (in the frontal, lateral temporal, parietal and retrosplenial cortices, FLR region) and entorhinal tau deposition. Results: In 410 participants (mean age 40 ± 8 years at remote exam, 56 ± 8 years recent exam), the mean time between the remote exam BP measurement and PET was 16 ± 2 years. A steep change (slope of ≥0.5 or ≤−0.5 mmHg/year) in DBP over early to mid-life was associated with increased entorhinal tau-PET deposition (β = 0.02; 95% CI = 0.01, 0.04; p = 0.047), driven by a steep decline in DBP (β = 0.04; 95% CI = 0.01, 0.07; p = 0.01). Persistent hypertension, new-onset hypertension, resolved hypertension or a steep change in SBP were not associated with amyloid or tau burden. Conclusions: In adults without clinical dementia, a steep DBP decline from early mid-life into mid-life was associated with tau deposition in the entorhinal cortex, one of the earliest affected regions in Alzheimer's disease. Maintaining normotension across the ∼15–16 years mid-life period may reduce the future risk of tau-PET burden in the brain.

5 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MMMartin Mulligan
Martin Mulligan
ABAlexa S. Beiser
Alexa S. Beiser
SGSaptaparni Ghosh
Saptaparni Ghosh
ABAyantika Banerjee
Ayantika Banerjee
HAHugo Aparicio
Hugo Aparicio
EMEmer R McGrath
Emer R McGrath
Background: Nerve growth factor (NGF) is associated with neuroprotection and neural repair. However, whether NGF is associated with future stroke in humans is unknown. We determined the association between late midlife serum NGF and subsequent risk of clinical stroke, covert brain infarcts, and white matter hyperintensity volume on magnetic resonance imaging. Methods: A total of 1709 stroke‐free participants from the FHS (Framingham Heart Study) Offspring and Omni 1 cohorts who attended Offspring examination 7/Omni 1 examination 2, respectively (1998–2001), with baseline serum NGF were included. The primary outcomes were incident all‐cause and ischemic stroke. Secondary outcomes included covert brain infarct and white matter hyperintensity volume on magnetic resonance imaging. Serum NGF was analyzed continuously and by tertiles, adjusting for age, sex, and vascular risk factors. Cox proportional hazards regression models were used to assess the association between serum NGF and all‐cause and ischemic stroke risk. Linear and logistic regression models were used to evaluate the association between serum NGF levels and white matter hyperintensity volume and covert brain infarct. Results: Mean age was 60.6±9.6 years, and 47.6% were men. The median follow‐up for incident stroke was 19.2 (interquartile range, 14.7–21.3) years. The highest tertile (tertile 3) of NGF, compared with the bottom tertile (tertile 1), was associated with a reduced risk of incident all‐cause stroke (hazard ratio [HR], 0.59 [95% CI, 0.37–0.94]; P =0.03) and ischemic stroke (HR, 0.50 [95% CI, 0.27–0.77]; P =0.003). Tertile 3 versus tertile 1 of NGF was also associated with a reduced risk of covert brain infarct (odds ratio, 0.57 [95% CI, 0.34–0.97]; P =0.04). Conclusions: Higher serum NGF in late midlife demonstrates a protective association with future risk of silent and clinically overt stroke.

1 November 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
LCLeroy L. Cooper
Leroy L. Cooper
ABAyantika Banerjee
Ayantika Banerjee
ABAlexa S. Beiser
Alexa S. Beiser
SCSokratis Charisis
Sokratis Charisis
DHDavid J. Hamel-Sellman
David J. Hamel-Sellman
GMGary F. Mitchell
Gary F. Mitchell
BACKGROUND: Accelerated vascular aging, assessed as artificial intelligence–based vascular age (AIVA), is associated with small vessel disease that may impact brain structure and neuropsychological function. METHODS: In a cross-section of Framingham Heart Study participants, AIVA was estimated using a validated convolutional neural network trained to predict carotid-femoral pulse wave velocity from a normalized pressure waveform. Brain structure was assessed using magnetic resonance imaging with diffusion tensor imaging, and neuropsychological function was assessed using a standardized test battery. Analyses included magnetic resonance imaging (N=2313) and neuropsychological (N=3001) samples. We used multivariable linear and logistic regression to relate AIVA to brain structural and neuropsychological functional measures. RESULTS: The mean±SD age across participants was 62±11 years; 56% were women. In multivariable models, higher AIVA was associated with worse markers of cerebral small vessel disease (mean white matter free water: β [per SD], 0.09 [95% CI, 0.04–0.14]; P <0.001; peak width of skeletonized mean diffusivity: β , 0.05 [95% CI, 0.00–0.10]; P =0.045; white matter hyperintensity volume: β , 0.08 [95% CI, 0.03–0.12]; P <0.001) and higher odds of cerebrovascular injury (presence of extensive white matter hyperintensities: odds ratio [per SD], 1.22 [95% CI, 1.02–1.47]; P =0.03; presence of brain infarcts: odds ratio, 1.44 [95% CI, 1.02–2.04]; P =0.04). In addition, higher AIVA was associated with worse performance on Trails B-A ( β , −0.05 [95% CI, −0.10 to −0.01]; P =0.03), similarities ( β , −0.06 [95% CI, −0.11 to −0.01]; P =0.02), and global cognition ( β , − 0.07 [95% CI, −0.12 to −0.03]; P =0.002) and higher odds of prevalent depressive symptoms (odds ratio, 1.24 [95% CI, 1.08–1.41]; P =0.002) and high Center for Epidemiologic Studies Depression Scale score (odds ratio, 1.20 [95% CI, 1.00–1.44]; P =0.047). Vascular brain injury markers partially mediated the associations of AIVA with global cognition score and presence of depressive symptoms. CONCLUSIONS: Peripheral pressure waveform AIVA may be a novel, noninvasive indicator of subclinical vascular brain injury and neuropsychological function.